Ashok Kumar Gangopadhyay
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ashok Kumar Gangopadhyay.
European Journal of Medicinal Chemistry | 2012
Ravindra Dnyandev Jadhav; Kishorkumar S. Kadam; Shivaji Kandre; Tandra Guha; M. Mahesh Kumar Reddy; Manoja K. Brahma; Nitin J. Deshmukh; Amol Dixit; Lalit S. Doshi; Nisha Potdar; Arno A. Enose; Ram A. Vishwakarma; H. Sivaramakrishnan; Shaila Srinivasan; Kumar V.S. Nemmani; Amol Gupte; Ashok Kumar Gangopadhyay; Rajiv Sharma
Diacylglycerol acyltransferase, DGAT1, is a promising target enzyme for obesity due to its involvement in the committed step of triglyceride biosynthesis. Amino biphenyl carboxylic acids, exemplified by compound 4, are known potent inhibitors of hDGAT1. However the high cLogP and poor solubility of these biphenyl analogs might tend to limit their development. We have synthesized and evaluated compounds containing 3-phenylisoxazole, 5-phenyloxazole, and 3-phenyl-1,2,4-oxadiazole biaryl units for their hDGAT1 inhibition. Our aim in synthesizing such heterocyclic analogs was to improve the cLogP and solubility of these molecules while retaining hDGAT1 potency. Several compounds within the 3-phenylisoxazole series exhibited potent hDGAT1 inhibition when evaluated using an in vitro enzymatic assay. Certain promising compounds were studied for their potential to reduce triglyceride levels using an in vivo fat tolerance test in mice and were also evaluated for any possible improvement to their solubility. Compound 40a (IC(50) = 64 nM) with an in vivo plasma triglyceride reduction of 90 percent, and a solubility of 0.43 mg/ml at pH 7.4 may serve as a new lead for developing newer anti-obesity agents.
Bioorganic & Medicinal Chemistry | 1998
Bansi Lal; Ashok Kumar Gangopadhyay; Ramanujam Rajagopalan; Anil Vasantrao Ghate
Using appropriate protection and deprotection sequence novel hydroxyacyl chains of the type CO(CH2)nOH are synthesized and are utilized to develop new analogues of forskolin. Several compounds showed good positive inotropic activity. Compound 12 is almost 10 times more active than forskolin (EC50 = 0.002 microgram/ml).].
Bioorganic & Medicinal Chemistry | 1998
Bansi Lal; Ashok Kumar Gangopadhyay; Ramesh M. Gidwani; Magno Fernandes; Ramanujam Rajagopalan; Anil Vasantrao Ghate
Using the novel lead from hydroxy acetyl substituted forskolin analogues, such as 7 beta-hydroxyacetyl-7 beta-deacetyl forskolin or 6 beta-hydroxyacetyl forskolin, a number of water soluble omega-amino acyl derivatives were synthesized. Two such compounds 6 and 18 showed better in vitro activity but failed to show in vivo activity.
Synthetic Communications | 2007
Ashok Kumar Gangopadhyay; Gopal Vishnu Gole; Ravindra Dnyandev Jadhav; Bansi Lal
Abstract This article describes a simple method for the synthesis of roxifiban, a potent glycoprotein GP IIb‐IIIa receptor antagonist, by a diastereoselective coupling approach to give >99.9% optical purity. We have also described an attempt to resolve the key synthetic intermediate by diastereomeric ester formation. Although we have been able to separate two diastereomeric esters, the removal of the chiral auxiliary led to partial racemization.
Synthetic Communications | 2006
Ashok Kumar Gangopadhyay; Bansi Lal
Abstract While removing the TBDMS group from OH protection, a novel epoxidation reaction occurred across acrylate ester attached to a forskolin fragment. Besides spectroscopic data, the epoxide formation was confirmed by ring opening with a secondary amine. This unique epoxidation reaction, to our knowledge, is not known in the literature. This reaction led us to discover a simple deblocking protocol. The epoxide and the desired Michael substrates were used to introduce imidazole into forskolin.
Synthetic Communications | 2007
Ashok Kumar Gangopadhyay; Bansi Lal
Abstract This article describes a systematic study for the introduction of ω‐guanidine function at a late stage of synthesis using a protected amino group as a surrogate to improve overall yield. This concept was used to design and synthesize pseudo‐peptides as GP IIb–IIIa receptor antagonist wherein glycine in endogenous ligand Arg‐Gly‐Asp (RGD) is replaced by 2‐amino‐thiazole‐4‐ylacetic acid (Tha) as a spacer. Further, we describe here a unique salt exchange cum purification technology based on reverse phase (RP‐18) medium‐pressure liquid chromatography.
Journal of The Chemical Society-perkin Transactions 1 | 1992
Bansi Lal; Ashok Kumar Gangopadhyay
Reaction of different phosphorylating agents such as POCl3, bis-(p-methoxyphenyl) phosphorochloridate, 2-chloro-2-oxo-1,3,2-dioxaphospholane and bis-(trifluoroethyl) phosphite with forskolin gave the corresponding isomers α- and β-1, 9-cyclic phosphates/phosphites. 1,2-Dibromo-2-phenylethylphosphonic acid reacted with forskolin and 7-deacetylforskolin to give forskolin 1-phosphate 17 and 7-deacetylforskolin 7-phosphate 18, respectively.
Bioorganic & Medicinal Chemistry | 2003
Bansi Lal; Vitthal Genbhau Gund; Ashok Kumar Gangopadhyay; S.R. Nadkarni; Vidula Dikshit; Dipak Kumar Chatterjee; R. Shirvaikar
Journal of Heterocyclic Chemistry | 2013
Ravindra Dnyandev Jadhav; Hitesh D. Mistry; Hashim Motiwala; Kishorkumar S. Kadam; Shivaji Kandre; Amol Gupte; Ashok Kumar Gangopadhyay; Rajiv Sharma
Archive | 2008
Vijay Singh Chauhan; Ashish Suthar; Dhananjay Sapre; Swati Bal-Tembe; Ashok Kumar Gangopadhyay; Asha Kulkarni-Almeida; Sapna Parikh; Ravindra Dattatraya Gupte; Nilesh M. Dagia; Somesh Sharma; Shruta S. Dadarkar; Mahesh G. Jadhav; Aditi Amol Tannu